profit from every $100 of sales.
$0$100
CEL-SCI
$1.35-6.90% today
-80.8% in 1 year
1-year low $0.971-year high $7.67
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What CEL-SCI sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$25.4 million of profit last year.
SalesProfit
CEL-SCI vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| CEL-SCI | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads CEL-SCI's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -36 | -31 | -26 | -25 | |
| -32 | -28 | -22 | -21 | |
| -37 | -32 | -27 | -25 | |
| -26.10 | -21.90 | -15.31 | -6.27 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 51 | 31 | 27 | 28 |
| Cash | 23 | 4 | 5 | 11 |
| Total debt | 15 | 14 | 12 | 9 |
| Total liabilities | 18 | 17 | 14 | 12 |
| 32 | 13 | 13 | 16 | |
| 1 | 1 | 2 | 4 | |
| -59.3% | -93.0% | -84.4% | -77.2% | |
| -114.1% | -243.6% | -209.2% | -159.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -18 | -23 | -19 | -17 | |
| 1 | 0 | 0 | 0 | |
| -19 | -23 | -19 | -17 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 12 | 7 | 5 | 3 |
Valuation
- –
- –
- –
- 0.9×
- –
- –
- –
- -72,258.4%
- -107.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -114.3%
- -93.1%
- -226.1%
- -104.0%
- -130.4%
- –
Growth
- –
- –
- −90,653.1%
- –
- +31.5%
Financial health
- -0.2×
- 0.95
- 46.4%
- -41.1×
- 1.39
- 1.35
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.67 | – | – |
| Feb 17, 2026 | -0.68 | – | – |
| Jan 12, 2026 | -2.70 | – | – |
| Aug 14, 2025 | -1.36 | – | – |
| May 14, 2025 | -2.40 | – | – |
| Feb 14, 2025 | -3.30 | – | – |
| Jan 13, 2025 | -2.70 | -3.00 | +10.0% |
| Aug 14, 2024 | -4.20 | -3.60 | −16.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
53No pass
Philip Fisher
30No pass
Peter Lynch
44No pass
Joel Greenblatt
0No pass
Charlie Munger
17No pass
Terry Smith
22No pass
Questions about CEL-SCI
Is CEL-SCI a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the CEL-SCI AI analysis
What does CEL-SCI do?
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. It is in Biotechnology.
Does CEL-SCI pay a dividend?
No. CEL-SCI does not pay a dividend at the moment.
Is CEL-SCI stock halal?
No. CEL-SCI does not pass our halal screen: its debt is 40% of its market value, at or above the 33% limit. How we check
How has CEL-SCI stock done over the past year?
Down 80.8% over the past twelve months, to $1.35. It traded between $0.97 and $7.67 and is 82.4% below its high.
Who are CEL-SCI's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with CEL-SCI's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.